What do systematic reviews say?

Intervention not reported

• Methotrexate for treating rheumatoid arthritis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 298 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in health‐Related Quality of Life at least 20% improvement (moderate certainty).

• Methotrexate for treating rheumatoid arthritis 2014 · Cochrane Headline outcomes only
  RR 1.5 [1, 2.1]
  1 study · 263 participants
  Moderate

Intervention not reported

The intervention probably leads to lower radiographic Progression Increase in erosion scores of > 3 units (moderate certainty).

• Methotrexate for treating rheumatoid arthritis 2014 · Cochrane Headline outcomes only
  RR 0.31 [0.11, 0.86]
  1 study · 219 participants
  Moderate

Intervention not reported

The intervention leads to higher discontinuations due to adverse events (high certainty).

• Methotrexate for treating rheumatoid arthritis 2014 · Cochrane Headline outcomes only
  RR 2.1 [1.3, 3.3]
  6 studies · 613 participants
  High

Intervention not reported

The intervention showed no clear difference in serious Adverse Events (moderate certainty).

• Methotrexate for treating rheumatoid arthritis 2014 · Cochrane Headline outcomes only
  RR 1.4 [0.36, 5.7]
  2 studies · 330 participants
  Moderate

MTX treated vs no MTX treated

The review found no eligible studies for this question.

• Methotrexate for ankylosing spondylitis 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

MTX treated vs no MTX treated

The review found no eligible studies for this question.

• Methotrexate for ankylosing spondylitis 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

MTX treated vs no MTX treated

• Methotrexate for ankylosing spondylitis 2013 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 35 participants
  Low

MTX treated vs no MTX treated

The review found no eligible studies for this question.

• Methotrexate for ankylosing spondylitis 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

MTX treated vs no MTX treated

The review found no eligible studies for this question.

• Methotrexate for ankylosing spondylitis 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

MTX treated vs no MTX treated

The review found no eligible studies for this question.

• Methotrexate for ankylosing spondylitis 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

MTX treated vs no MTX treated

MTX treated showed no clear difference in withdrawal for any reason compared with no MTX treated (low certainty).

• Methotrexate for ankylosing spondylitis 2013 · Cochrane Headline outcomes only
  RR 1.06 [0.07, 15.62]
  1 study · 35 participants
  Low

MTX combination vs MTX monotherapy

MTX combination showed no clear difference in ACR 50 response of DMARDs naive patients Number of responders compared with MTX monotherapy (low certainty).

• Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic… 2010 · Cochrane Headline outcomes only
  RR 1.76 [0.64, 4.85]
  2 studies · 127 participants
  Low

MTX combination vs MTX monotherapy

MTX combination probably leads to higher ACR 50 response of MTX inadequate responders number of responders compared with MTX monotherapy (moderate certainty).

• Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic… 2010 · Cochrane Headline outcomes only
  RR 4.54 [2.51, 8.2]
  3 studies · 404 participants
  Moderate

MTX combination vs MTX monotherapy

MTX combination showed no clear difference in ACR 50 response of non‐MTX DMARDs inadequate responders number of… compared with MTX monotherapy (moderate certainty).

• Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic… 2010 · Cochrane Headline outcomes only
  RR 1.68 [0.94, 2.99]
  2 studies · 158 participants
  Moderate

MTX combination vs MTX monotherapy

MTX combination showed no clear difference in withdrawal due to lack of efficacy or toxicity of DMARDs naive… compared with MTX monotherapy (moderate certainty).

• Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic… 2010 · Cochrane Headline outcomes only
  RR 1.16 [0.7, 1.93]
  5 studies · 405 participants
  Moderate

MTX combination vs MTX monotherapy

MTX combination showed no clear difference in withdrawal due to lack of efficacy or toxicity of MTX inadequate… compared with MTX monotherapy (moderate certainty).

• Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic… 2010 · Cochrane Headline outcomes only
  RR 0.86 [0.49, 1.51]
  3 studies · 476 participants
  Moderate

MTX combination vs MTX monotherapy

It is very uncertain whether MTX combination changes withdrawal due to lack of efficacy or toxicity of non‐MTX DMARDs… compared with MTX monotherapy (very low certainty).

• Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic… 2010 · Cochrane Headline outcomes only
  RR 0.75 [0.41, 1.35]
  5 studies · 329 participants
  Very low

MTX combination vs MTX monotherapy

It is very uncertain whether MTX combination changes withdrawal due to adverse reactions (Pooled across regimens) number… compared with MTX monotherapy (very low certainty).

• Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic… 2010 · Cochrane Headline outcomes only
  RR 1.59 [1.2, 2.12]
  17 studies · 1624 participants
  Very low